Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

DTC Special Feature: What now?

HHS announced its new price transparency rules for direct-to-consumer TV ads. Now the industry has to sort out what to do about them.

Read More »

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Read More »

Agenda 2019: Choose your own adventure

Med Ad News asked its sources for the Agenda 2019 special feature which key questions for 2019 we’d left out. This is what they told us.

Read More »

Ad-ventures in Marketing XI

For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.

Read More »

AbbVie 2018: Still Humira

While other products are showing signs of growth, the fate of AbbVie is still in the hands of the iconic autoimmune drug.

Read More »

Bristol-Myers Squibb 2018: The future is now

With two potential $6 billion brands now at the top of the company’s portfolio, Bristol-Myers Squibb is officially through the lean times.

Read More »

Gilead 2018: The party’s over

On the far side of the company’s brief but transformative adventure with Sovaldi and Harvoni, Gilead is returning to earth with a solid portfolio of HIV drugs.

Read More »

Lilly 2018: Off the roller coaster

With new products showing signs of impressive growth, Eli Lilly seems safely past the company’s recent patent trough.

Read More »

Merck 2018: The $6 billion surprise

Nine years ago Keytruda was about to be out-licensed. Now Keytruda is Merck’s top-selling medicine.

Read More »

First Year After Launch Special Feature 2018: Don’t look back, someone might be gaining

The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom